Drug intelligence / Profile preview

CALT-GM-NVs

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CALT-GM-NVs (dual-targeted nanovesicles) is a nanomedicine platform designed to target cancer stem-like cells (CSCs) in hepatocellular carcinoma (HCC). The therapeutic mechanism involves inducing differentiation of cancer stem-like cells, which are responsible for tumor heterogeneity and radiotherapy resistance[1]. RNA sequencing analysis demonstrated that CALT-GM-NVs downregulate oncogenic signaling pathways while upregulating pathways associated with cellular differentiation[1]. This dual-targeted approach addresses the highly plastic nature of cancer stem-like cells that drive therapeutic resistance in HCC.

Targets

PIN1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1)NOTCH (Neurogenic locus notch homolog protein 3)

Beyond the preview

Go deeper on CALT-GM-NVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CALT-GM-NVs.

Explore the full profile